<DOC>
	<DOCNO>NCT00528892</DOCNO>
	<brief_summary>The investigator hypothesis switch ritonavir-boosted PI raltegravir may associate least non-inferior effectiveness , virological response safety , even good tolerability profile regard lipid metabolism , insulin resistance , body fat distribution compare continuation baseline regimen HIV-1 seropositive male female least 18 year age old ritonavir-boosted PI plus least 2 drug plasma viral RNA 50 copies/mL .</brief_summary>
	<brief_title>Switching From PI RALtegravir HIV Stable Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patient male female least 18 year age . Women childbearing potential must negative serum pregnancy test ( HCG ) within 10 day prior randomization study . Patients must use adequate birth control measure ( barrier method . ) Patients must HIV 1 seropositive use standard diagnostic criterion . Patients must two plasma viral RNA measurement detection limit routine ultrasensitive method use participate site ( least &lt; 50 copies/mL ) within 180 day prior randomization study . Patients must continuous therapy HAART consist ritonavirboosted proteaseinhibitor ( PI ) least two antiretroviral agent least 6 month prior randomization study , plan drug change follow 12 month . Boosted PIs indinavir , fosamprenavir , saquinavir , lopinavir , atazanavir , tipranavir darunavir . Patients must consider clinically stable , opinion investigator , time entry study ; i.e. , clinical status chronic medication unchanged least 14 day prior randomization . Patients currently receive treatment opportunistic infection may allow study long criteria met . Prophylaxis opportunistic infection consistent standard treatment permissible . . The following laboratory value must obtain within 24 week randomization study : Hemoglobin &gt; 8.0 g/dL . Absolute neutrophil count &gt; 750/mm3 Platelet count &gt; 50,000/ mm3 Creatinine &lt; 2.0 mg/dL . Transaminases ( ALAT , ASAT ) &lt; 5xULN Pregnancy breast feed woman plan pregnancy study duration . Patients ART regimens likely maintain whole study duration Prior use HIV integrase inhibitor . Use investigational agent ( ART expand access programme ) within 90 day randomization . Alcohol substance abuse opinion investigator would interfere patient compliance safety . Patients active opportunistic infection malignancy . Patients chronic , stable opportunistic infection allow enter study . Any condition history illness , opinion investigator , might confound result study pose additional risk administer study drug patient . Any patient diagnosis visceral Kaposi 's sarcoma . Patients lymphedema secondary cutaneous Kaposi 's sarcoma , cutaneous palatal Kaposi 's sarcoma treat systemic immunosuppressive therapy must also exclude . Any patient diagnosis acute hepatitis due cause . Patients chronic hepatitis include chronic hepatitis B surface antigenemia chronic hepatitis C may enter study long stable liver function test meet inclusion criterion . Patients acute exacerbation chronic hepatitis exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>